Global Paclitaxel

Paclitaxel Comprehensive Study by Type (Natural Paclitaxel, Semi-synthetic Paclitaxel), Application (Breast Cancer, Ovarian Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Stomach Cancer, Others), End User (Hospitals, Clinics, Cancer research institutes) Players and Region - Global Market Outlook to 2024

Paclitaxel Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Paclitaxel Market Overview:
Paclitaxel is an antineoplastic agent which acts by an inhibitor of cellular mitosis and it is used in chemotherapy medications for the treatment of various types of cancer. It is primarily being used for the treatment of ovarian, breast, and lung cancer. Therapy with paclitaxel has been linked with a low rate of serum enzyme elevations however has not been clearly linked to cases of clinically apparent acute liver injury. The drug was isolated from the bark of the Pacific yew tree. Owing to the rising prevalence of cancer, the demand for paclitaxel has surged across the globe. Some of the key players profiled in the study are Phyton Biotech (Canada), ScinoPharm (Taiwan), Novasep Inc. (United States), Samyang (Korea), Polymed (United States), TAPI (Teva) (United Kingdom), Fresenius-kabi (Germany), Southpharma (Serbia), Haiyao (China) and Huiang Biopharma (China).

On the basis of geography, the market of Paclitaxel has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Asia Pacific on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Paclitaxel market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • The Use of Paclitaxel in Treating Various Types of Cancer with High Efficiency and Positive Results
  • Increase in the Incidences of Cancer Diseases
  • The Ease in Availability of Paclitaxel and Development of This Drug
  • Advanced Technologies and Awareness towards the Treatments


Restraints
  • The Adverse Effects with Usage of This Drug and Various Side Effects

Opportunities
  • Emerging Demand from Economies




Target Audience:
Paclitaxel Manufactures, Paclitaxel Distributors, Paclitaxel Importer/Exporter, Research & Consultant Firms, Regulatory & Government Bodies and Downstream Vendors

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Paclitaxel market on the basis of product [Natural Paclitaxel and Semi-synthetic Paclitaxel] , application [Breast Cancer, Ovarian Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Stomach Cancer and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Paclitaxel market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Paclitaxel industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Yunnan Hande (China) and Hainan Yew Pharm (China).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Paclitaxel market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.

Report Objectives / Segmentation Covered

By Type
  • Natural Paclitaxel
  • Semi-synthetic Paclitaxel
By Application
  • Breast Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Prostate Cancer
  • Lung Cancer
  • Stomach Cancer
  • Others
By End User
  • Hospitals
  • Clinics
  • Cancer research institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Use of Paclitaxel in Treating Various Types of Cancer with High Efficiency and Positive Results
      • 3.2.2. Increase in the Incidences of Cancer Diseases
      • 3.2.3. The Ease in Availability of Paclitaxel and Development of This Drug
      • 3.2.4. Advanced Technologies and Awareness towards the Treatments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Paclitaxel, by Type, Application, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Paclitaxel (Value)
      • 5.2.1. Global Paclitaxel by: Type (Value)
        • 5.2.1.1. Natural Paclitaxel
        • 5.2.1.2. Semi-synthetic Paclitaxel
      • 5.2.2. Global Paclitaxel by: Application (Value)
        • 5.2.2.1. Breast Cancer
        • 5.2.2.2. Ovarian Cancer
        • 5.2.2.3. Cervical Cancer
        • 5.2.2.4. Prostate Cancer
        • 5.2.2.5. Lung Cancer
        • 5.2.2.6. Stomach Cancer
        • 5.2.2.7. Others
      • 5.2.3. Global Paclitaxel by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Cancer research institutes
      • 5.2.4. Global Paclitaxel Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Paclitaxel: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Phyton Biotech (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ScinoPharm (Taiwan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novasep Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Samyang (Korea)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Polymed (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. TAPI (Teva) (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fresenius-kabi (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Southpharma (Serbia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Haiyao (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Huiang Biopharma (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Paclitaxel Sale, by Type, Application, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Paclitaxel (Value)
      • 7.2.1. Global Paclitaxel by: Type (Value)
        • 7.2.1.1. Natural Paclitaxel
        • 7.2.1.2. Semi-synthetic Paclitaxel
      • 7.2.2. Global Paclitaxel by: Application (Value)
        • 7.2.2.1. Breast Cancer
        • 7.2.2.2. Ovarian Cancer
        • 7.2.2.3. Cervical Cancer
        • 7.2.2.4. Prostate Cancer
        • 7.2.2.5. Lung Cancer
        • 7.2.2.6. Stomach Cancer
        • 7.2.2.7. Others
      • 7.2.3. Global Paclitaxel by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Cancer research institutes
      • 7.2.4. Global Paclitaxel Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Paclitaxel: by Type(USD Million)
  • Table 2. Paclitaxel Natural Paclitaxel , by Region USD Million (2013-2018)
  • Table 3. Paclitaxel Semi-synthetic Paclitaxel , by Region USD Million (2013-2018)
  • Table 4. Paclitaxel: by Application(USD Million)
  • Table 5. Paclitaxel Breast Cancer , by Region USD Million (2013-2018)
  • Table 6. Paclitaxel Ovarian Cancer , by Region USD Million (2013-2018)
  • Table 7. Paclitaxel Cervical Cancer , by Region USD Million (2013-2018)
  • Table 8. Paclitaxel Prostate Cancer , by Region USD Million (2013-2018)
  • Table 9. Paclitaxel Lung Cancer , by Region USD Million (2013-2018)
  • Table 10. Paclitaxel Stomach Cancer , by Region USD Million (2013-2018)
  • Table 11. Paclitaxel Others , by Region USD Million (2013-2018)
  • Table 12. Paclitaxel: by End User(USD Million)
  • Table 13. Paclitaxel Hospitals , by Region USD Million (2013-2018)
  • Table 14. Paclitaxel Clinics , by Region USD Million (2013-2018)
  • Table 15. Paclitaxel Cancer research institutes , by Region USD Million (2013-2018)
  • Table 16. South America Paclitaxel, by Country USD Million (2013-2018)
  • Table 17. South America Paclitaxel, by Type USD Million (2013-2018)
  • Table 18. South America Paclitaxel, by Application USD Million (2013-2018)
  • Table 19. South America Paclitaxel, by End User USD Million (2013-2018)
  • Table 20. Brazil Paclitaxel, by Type USD Million (2013-2018)
  • Table 21. Brazil Paclitaxel, by Application USD Million (2013-2018)
  • Table 22. Brazil Paclitaxel, by End User USD Million (2013-2018)
  • Table 23. Argentina Paclitaxel, by Type USD Million (2013-2018)
  • Table 24. Argentina Paclitaxel, by Application USD Million (2013-2018)
  • Table 25. Argentina Paclitaxel, by End User USD Million (2013-2018)
  • Table 26. Rest of South America Paclitaxel, by Type USD Million (2013-2018)
  • Table 27. Rest of South America Paclitaxel, by Application USD Million (2013-2018)
  • Table 28. Rest of South America Paclitaxel, by End User USD Million (2013-2018)
  • Table 29. Asia Pacific Paclitaxel, by Country USD Million (2013-2018)
  • Table 30. Asia Pacific Paclitaxel, by Type USD Million (2013-2018)
  • Table 31. Asia Pacific Paclitaxel, by Application USD Million (2013-2018)
  • Table 32. Asia Pacific Paclitaxel, by End User USD Million (2013-2018)
  • Table 33. China Paclitaxel, by Type USD Million (2013-2018)
  • Table 34. China Paclitaxel, by Application USD Million (2013-2018)
  • Table 35. China Paclitaxel, by End User USD Million (2013-2018)
  • Table 36. Japan Paclitaxel, by Type USD Million (2013-2018)
  • Table 37. Japan Paclitaxel, by Application USD Million (2013-2018)
  • Table 38. Japan Paclitaxel, by End User USD Million (2013-2018)
  • Table 39. India Paclitaxel, by Type USD Million (2013-2018)
  • Table 40. India Paclitaxel, by Application USD Million (2013-2018)
  • Table 41. India Paclitaxel, by End User USD Million (2013-2018)
  • Table 42. South Korea Paclitaxel, by Type USD Million (2013-2018)
  • Table 43. South Korea Paclitaxel, by Application USD Million (2013-2018)
  • Table 44. South Korea Paclitaxel, by End User USD Million (2013-2018)
  • Table 45. Taiwan Paclitaxel, by Type USD Million (2013-2018)
  • Table 46. Taiwan Paclitaxel, by Application USD Million (2013-2018)
  • Table 47. Taiwan Paclitaxel, by End User USD Million (2013-2018)
  • Table 48. Australia Paclitaxel, by Type USD Million (2013-2018)
  • Table 49. Australia Paclitaxel, by Application USD Million (2013-2018)
  • Table 50. Australia Paclitaxel, by End User USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Paclitaxel, by Type USD Million (2013-2018)
  • Table 52. Rest of Asia-Pacific Paclitaxel, by Application USD Million (2013-2018)
  • Table 53. Rest of Asia-Pacific Paclitaxel, by End User USD Million (2013-2018)
  • Table 54. Europe Paclitaxel, by Country USD Million (2013-2018)
  • Table 55. Europe Paclitaxel, by Type USD Million (2013-2018)
  • Table 56. Europe Paclitaxel, by Application USD Million (2013-2018)
  • Table 57. Europe Paclitaxel, by End User USD Million (2013-2018)
  • Table 58. Germany Paclitaxel, by Type USD Million (2013-2018)
  • Table 59. Germany Paclitaxel, by Application USD Million (2013-2018)
  • Table 60. Germany Paclitaxel, by End User USD Million (2013-2018)
  • Table 61. France Paclitaxel, by Type USD Million (2013-2018)
  • Table 62. France Paclitaxel, by Application USD Million (2013-2018)
  • Table 63. France Paclitaxel, by End User USD Million (2013-2018)
  • Table 64. Italy Paclitaxel, by Type USD Million (2013-2018)
  • Table 65. Italy Paclitaxel, by Application USD Million (2013-2018)
  • Table 66. Italy Paclitaxel, by End User USD Million (2013-2018)
  • Table 67. United Kingdom Paclitaxel, by Type USD Million (2013-2018)
  • Table 68. United Kingdom Paclitaxel, by Application USD Million (2013-2018)
  • Table 69. United Kingdom Paclitaxel, by End User USD Million (2013-2018)
  • Table 70. Netherlands Paclitaxel, by Type USD Million (2013-2018)
  • Table 71. Netherlands Paclitaxel, by Application USD Million (2013-2018)
  • Table 72. Netherlands Paclitaxel, by End User USD Million (2013-2018)
  • Table 73. Rest of Europe Paclitaxel, by Type USD Million (2013-2018)
  • Table 74. Rest of Europe Paclitaxel, by Application USD Million (2013-2018)
  • Table 75. Rest of Europe Paclitaxel, by End User USD Million (2013-2018)
  • Table 76. MEA Paclitaxel, by Country USD Million (2013-2018)
  • Table 77. MEA Paclitaxel, by Type USD Million (2013-2018)
  • Table 78. MEA Paclitaxel, by Application USD Million (2013-2018)
  • Table 79. MEA Paclitaxel, by End User USD Million (2013-2018)
  • Table 80. Middle East Paclitaxel, by Type USD Million (2013-2018)
  • Table 81. Middle East Paclitaxel, by Application USD Million (2013-2018)
  • Table 82. Middle East Paclitaxel, by End User USD Million (2013-2018)
  • Table 83. Africa Paclitaxel, by Type USD Million (2013-2018)
  • Table 84. Africa Paclitaxel, by Application USD Million (2013-2018)
  • Table 85. Africa Paclitaxel, by End User USD Million (2013-2018)
  • Table 86. North America Paclitaxel, by Country USD Million (2013-2018)
  • Table 87. North America Paclitaxel, by Type USD Million (2013-2018)
  • Table 88. North America Paclitaxel, by Application USD Million (2013-2018)
  • Table 89. North America Paclitaxel, by End User USD Million (2013-2018)
  • Table 90. United States Paclitaxel, by Type USD Million (2013-2018)
  • Table 91. United States Paclitaxel, by Application USD Million (2013-2018)
  • Table 92. United States Paclitaxel, by End User USD Million (2013-2018)
  • Table 93. Canada Paclitaxel, by Type USD Million (2013-2018)
  • Table 94. Canada Paclitaxel, by Application USD Million (2013-2018)
  • Table 95. Canada Paclitaxel, by End User USD Million (2013-2018)
  • Table 96. Mexico Paclitaxel, by Type USD Million (2013-2018)
  • Table 97. Mexico Paclitaxel, by Application USD Million (2013-2018)
  • Table 98. Mexico Paclitaxel, by End User USD Million (2013-2018)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Paclitaxel: by Type(USD Million)
  • Table 110. Paclitaxel Natural Paclitaxel , by Region USD Million (2019-2024)
  • Table 111. Paclitaxel Semi-synthetic Paclitaxel , by Region USD Million (2019-2024)
  • Table 112. Paclitaxel: by Application(USD Million)
  • Table 113. Paclitaxel Breast Cancer , by Region USD Million (2019-2024)
  • Table 114. Paclitaxel Ovarian Cancer , by Region USD Million (2019-2024)
  • Table 115. Paclitaxel Cervical Cancer , by Region USD Million (2019-2024)
  • Table 116. Paclitaxel Prostate Cancer , by Region USD Million (2019-2024)
  • Table 117. Paclitaxel Lung Cancer , by Region USD Million (2019-2024)
  • Table 118. Paclitaxel Stomach Cancer , by Region USD Million (2019-2024)
  • Table 119. Paclitaxel Others , by Region USD Million (2019-2024)
  • Table 120. Paclitaxel: by End User(USD Million)
  • Table 121. Paclitaxel Hospitals , by Region USD Million (2019-2024)
  • Table 122. Paclitaxel Clinics , by Region USD Million (2019-2024)
  • Table 123. Paclitaxel Cancer research institutes , by Region USD Million (2019-2024)
  • Table 124. South America Paclitaxel, by Country USD Million (2019-2024)
  • Table 125. South America Paclitaxel, by Type USD Million (2019-2024)
  • Table 126. South America Paclitaxel, by Application USD Million (2019-2024)
  • Table 127. South America Paclitaxel, by End User USD Million (2019-2024)
  • Table 128. Brazil Paclitaxel, by Type USD Million (2019-2024)
  • Table 129. Brazil Paclitaxel, by Application USD Million (2019-2024)
  • Table 130. Brazil Paclitaxel, by End User USD Million (2019-2024)
  • Table 131. Argentina Paclitaxel, by Type USD Million (2019-2024)
  • Table 132. Argentina Paclitaxel, by Application USD Million (2019-2024)
  • Table 133. Argentina Paclitaxel, by End User USD Million (2019-2024)
  • Table 134. Rest of South America Paclitaxel, by Type USD Million (2019-2024)
  • Table 135. Rest of South America Paclitaxel, by Application USD Million (2019-2024)
  • Table 136. Rest of South America Paclitaxel, by End User USD Million (2019-2024)
  • Table 137. Asia Pacific Paclitaxel, by Country USD Million (2019-2024)
  • Table 138. Asia Pacific Paclitaxel, by Type USD Million (2019-2024)
  • Table 139. Asia Pacific Paclitaxel, by Application USD Million (2019-2024)
  • Table 140. Asia Pacific Paclitaxel, by End User USD Million (2019-2024)
  • Table 141. China Paclitaxel, by Type USD Million (2019-2024)
  • Table 142. China Paclitaxel, by Application USD Million (2019-2024)
  • Table 143. China Paclitaxel, by End User USD Million (2019-2024)
  • Table 144. Japan Paclitaxel, by Type USD Million (2019-2024)
  • Table 145. Japan Paclitaxel, by Application USD Million (2019-2024)
  • Table 146. Japan Paclitaxel, by End User USD Million (2019-2024)
  • Table 147. India Paclitaxel, by Type USD Million (2019-2024)
  • Table 148. India Paclitaxel, by Application USD Million (2019-2024)
  • Table 149. India Paclitaxel, by End User USD Million (2019-2024)
  • Table 150. South Korea Paclitaxel, by Type USD Million (2019-2024)
  • Table 151. South Korea Paclitaxel, by Application USD Million (2019-2024)
  • Table 152. South Korea Paclitaxel, by End User USD Million (2019-2024)
  • Table 153. Taiwan Paclitaxel, by Type USD Million (2019-2024)
  • Table 154. Taiwan Paclitaxel, by Application USD Million (2019-2024)
  • Table 155. Taiwan Paclitaxel, by End User USD Million (2019-2024)
  • Table 156. Australia Paclitaxel, by Type USD Million (2019-2024)
  • Table 157. Australia Paclitaxel, by Application USD Million (2019-2024)
  • Table 158. Australia Paclitaxel, by End User USD Million (2019-2024)
  • Table 159. Rest of Asia-Pacific Paclitaxel, by Type USD Million (2019-2024)
  • Table 160. Rest of Asia-Pacific Paclitaxel, by Application USD Million (2019-2024)
  • Table 161. Rest of Asia-Pacific Paclitaxel, by End User USD Million (2019-2024)
  • Table 162. Europe Paclitaxel, by Country USD Million (2019-2024)
  • Table 163. Europe Paclitaxel, by Type USD Million (2019-2024)
  • Table 164. Europe Paclitaxel, by Application USD Million (2019-2024)
  • Table 165. Europe Paclitaxel, by End User USD Million (2019-2024)
  • Table 166. Germany Paclitaxel, by Type USD Million (2019-2024)
  • Table 167. Germany Paclitaxel, by Application USD Million (2019-2024)
  • Table 168. Germany Paclitaxel, by End User USD Million (2019-2024)
  • Table 169. France Paclitaxel, by Type USD Million (2019-2024)
  • Table 170. France Paclitaxel, by Application USD Million (2019-2024)
  • Table 171. France Paclitaxel, by End User USD Million (2019-2024)
  • Table 172. Italy Paclitaxel, by Type USD Million (2019-2024)
  • Table 173. Italy Paclitaxel, by Application USD Million (2019-2024)
  • Table 174. Italy Paclitaxel, by End User USD Million (2019-2024)
  • Table 175. United Kingdom Paclitaxel, by Type USD Million (2019-2024)
  • Table 176. United Kingdom Paclitaxel, by Application USD Million (2019-2024)
  • Table 177. United Kingdom Paclitaxel, by End User USD Million (2019-2024)
  • Table 178. Netherlands Paclitaxel, by Type USD Million (2019-2024)
  • Table 179. Netherlands Paclitaxel, by Application USD Million (2019-2024)
  • Table 180. Netherlands Paclitaxel, by End User USD Million (2019-2024)
  • Table 181. Rest of Europe Paclitaxel, by Type USD Million (2019-2024)
  • Table 182. Rest of Europe Paclitaxel, by Application USD Million (2019-2024)
  • Table 183. Rest of Europe Paclitaxel, by End User USD Million (2019-2024)
  • Table 184. MEA Paclitaxel, by Country USD Million (2019-2024)
  • Table 185. MEA Paclitaxel, by Type USD Million (2019-2024)
  • Table 186. MEA Paclitaxel, by Application USD Million (2019-2024)
  • Table 187. MEA Paclitaxel, by End User USD Million (2019-2024)
  • Table 188. Middle East Paclitaxel, by Type USD Million (2019-2024)
  • Table 189. Middle East Paclitaxel, by Application USD Million (2019-2024)
  • Table 190. Middle East Paclitaxel, by End User USD Million (2019-2024)
  • Table 191. Africa Paclitaxel, by Type USD Million (2019-2024)
  • Table 192. Africa Paclitaxel, by Application USD Million (2019-2024)
  • Table 193. Africa Paclitaxel, by End User USD Million (2019-2024)
  • Table 194. North America Paclitaxel, by Country USD Million (2019-2024)
  • Table 195. North America Paclitaxel, by Type USD Million (2019-2024)
  • Table 196. North America Paclitaxel, by Application USD Million (2019-2024)
  • Table 197. North America Paclitaxel, by End User USD Million (2019-2024)
  • Table 198. United States Paclitaxel, by Type USD Million (2019-2024)
  • Table 199. United States Paclitaxel, by Application USD Million (2019-2024)
  • Table 200. United States Paclitaxel, by End User USD Million (2019-2024)
  • Table 201. Canada Paclitaxel, by Type USD Million (2019-2024)
  • Table 202. Canada Paclitaxel, by Application USD Million (2019-2024)
  • Table 203. Canada Paclitaxel, by End User USD Million (2019-2024)
  • Table 204. Mexico Paclitaxel, by Type USD Million (2019-2024)
  • Table 205. Mexico Paclitaxel, by Application USD Million (2019-2024)
  • Table 206. Mexico Paclitaxel, by End User USD Million (2019-2024)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Paclitaxel: by Type USD Million (2013-2018)
  • Figure 5. Global Paclitaxel: by Application USD Million (2013-2018)
  • Figure 6. Global Paclitaxel: by End User USD Million (2013-2018)
  • Figure 7. South America Paclitaxel Share (%), by Country
  • Figure 8. Asia Pacific Paclitaxel Share (%), by Country
  • Figure 9. Europe Paclitaxel Share (%), by Country
  • Figure 10. MEA Paclitaxel Share (%), by Country
  • Figure 11. North America Paclitaxel Share (%), by Country
  • Figure 12. Global Paclitaxel share by Players 2018 (%)
  • Figure 13. Global Paclitaxel share by Players (Top 3) 2018(%)
  • Figure 14. Global Paclitaxel share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Phyton Biotech (Canada) Revenue, Net Income and Gross profit
  • Figure 17. Phyton Biotech (Canada) Revenue: by Geography 2018
  • Figure 18. ScinoPharm (Taiwan) Revenue, Net Income and Gross profit
  • Figure 19. ScinoPharm (Taiwan) Revenue: by Geography 2018
  • Figure 20. Novasep Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Novasep Inc. (United States) Revenue: by Geography 2018
  • Figure 22. Samyang (Korea) Revenue, Net Income and Gross profit
  • Figure 23. Samyang (Korea) Revenue: by Geography 2018
  • Figure 24. Polymed (United States) Revenue, Net Income and Gross profit
  • Figure 25. Polymed (United States) Revenue: by Geography 2018
  • Figure 26. TAPI (Teva) (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. TAPI (Teva) (United Kingdom) Revenue: by Geography 2018
  • Figure 28. Fresenius-kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Fresenius-kabi (Germany) Revenue: by Geography 2018
  • Figure 30. Southpharma (Serbia) Revenue, Net Income and Gross profit
  • Figure 31. Southpharma (Serbia) Revenue: by Geography 2018
  • Figure 32. Haiyao (China) Revenue, Net Income and Gross profit
  • Figure 33. Haiyao (China) Revenue: by Geography 2018
  • Figure 34. Huiang Biopharma (China) Revenue, Net Income and Gross profit
  • Figure 35. Huiang Biopharma (China) Revenue: by Geography 2018
  • Figure 36. Global Paclitaxel: by Type USD Million (2019-2024)
  • Figure 37. Global Paclitaxel: by Application USD Million (2019-2024)
  • Figure 38. Global Paclitaxel: by End User USD Million (2019-2024)
  • Figure 39. South America Paclitaxel Share (%), by Country
  • Figure 40. Asia Pacific Paclitaxel Share (%), by Country
  • Figure 41. Europe Paclitaxel Share (%), by Country
  • Figure 42. MEA Paclitaxel Share (%), by Country
  • Figure 43. North America Paclitaxel Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Phyton Biotech (Canada)
  • ScinoPharm (Taiwan)
  • Novasep Inc. (United States)
  • Samyang (Korea)
  • Polymed (United States)
  • TAPI (Teva) (United Kingdom)
  • Fresenius-kabi (Germany)
  • Southpharma (Serbia)
  • Haiyao (China)
  • Huiang Biopharma (China)
Additional players considered in the study are as follows:
Yunnan Hande (China) , Hainan Yew Pharm (China)
Select User Access Type

Key Highlights of Report


Feb 2019 245 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Paclitaxel Quantitative research analysis
Global Paclitaxel Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Paclitaxel Report?

Have a Query? Click Here

Other Related Reports

Cough Remedies Comprehensive Study by Type (Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stor...
$ 3650
Homeopathy Products Comprehensive Study by Type (Tincture, Dilutions, Ointments, Tablets, Others), Application (Analgesic & Antipyretic, Respiratory, Neurology, Immunology, Gastroenterology, Dermatol...
$ 3350
Vitamins Comprehensive Study by Type (Fat-soluble, Water-soluble), Application (Food & Beverages, Personal Care, Animal Feed, Pharmaceuticals), Distribution Channel (Hypermarket, Supermarket, Mass m...
$ 3450
Menopausal Hot Flashes Drug Comprehensive Study by Type (Capsule, Liniment, Tablet, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Treatment Type (Hormonal...
$ 3750
Smallpox Vaccine Comprehensive Study by Type (First Generation, Second Generation, Third Generation), Application (Vaccination) Players and Region - Global Market Outlook to 2026
$ 3500
Antifungal Drugs Comprehensive Study by Type (Gels, Cream, Shampoo, Injections, Liquids or Spray, Tablets (Pill)), Drugs (Azoles, Echinocandins, Polyenes, Others), Distribution Channel (Speciality cl...
$ 3750